Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction

BACKGROUND: Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The purpose of this study was to assess the safety and tolerability of Sacubitril/Valsartan in patient with HFrEF in P...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Nauman, Soomro, Najia Aslam, Naseeb, Khalid, Bhatti, Usman Hanif, Rauf, Rubina, Balouch, Iram Jehan, Moazzam, Ali, Bashir, Sonia, Ashraf, Tariq, Karim, Musa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012729/
https://www.ncbi.nlm.nih.gov/pubmed/36915075
http://dx.doi.org/10.1186/s12872-023-03070-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012729/
https://www.ncbi.nlm.nih.gov/pubmed/36915075
http://dx.doi.org/10.1186/s12872-023-03070-9

Ejemplares similares